Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

키워드

참고문헌 (15)

1. Park MJ, "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease : a network meta-analysis", Clin Mol Hepatol, 29, pp.693~704 (2023)
2. Ren TY, "Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease(MASLD) : one piece of the puzzle : Editorial on"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease : A network meta-analysis"", Clin Mol Hepatol, 30, pp.649~652 (2024)
3. Musso G, "Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis : a meta-analysis", JAMA Intern Med, 177, pp.633~640 (2017)
4. Armstrong MJ, "Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis(LEAN) : a multicentre, doubleblind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
5. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
6. Pellicoro A, "Liver fibrosis and repair : immune regulation of wound healing in a solid organ", Nat Rev Immunol, 14, pp.181~194 (2014)
7. Barb D, "Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease", Obesity(Silver Spring), 29, pp.1950~1960 (2021)
8. Nogami A, "Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease : present and future", Clin Mol Hepatol, 29(Suppl), pp.S123~S135 (2023)
9. Pasanta D, "Magnetic resonance spectroscopy of hepatic fat from fundamental to clinical applications", Diagnostics(Basel), 11, pp.842~ (2021)
10. Myers RP, "Controlled Attenuation Parameter(CAP) : a noninvasive method for the detection of hepatic steatosis based on transient elastography", Liver Int, 32, pp.902~910 (2012)
11. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
12. Kim HK, "Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity", Clin Mol Hepatol, 29, pp.987~1001 (2023)
13. Chan WK, "Comparison between obese and non-obese nonalcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S58~S67 (2023)
14. Simental-Mendía LE, "Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin : a metaanalysis of randomized controlled trials", Diabetes Res Clin Pract, 177, pp.108899~ (2021)
15. Jung YK, "Reversal of liver cirrhosis : current evidence and expectations", Korean J Intern Med, 32, pp.213~228 (2017)

관련 논문AI추천